Start Date
September 20, 2022
Primary Completion Date
May 27, 2023
Study Completion Date
August 10, 2023
700mg leronlimab weekly dose
leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5
80mg Regorafenib at week 1
Regorafenib is a small-molecule multiple kinase inhibitor
120mg Regorafenib at week2
Regorafenib is a small-molecule multiple kinase inhibitor
160 mg Regorafenib at week 3
Regorafenib is a small-molecule multiple kinase inhibitor
Lead Sponsor
Collaborators (1)
Amarex Clinical Research
OTHER
CytoDyn, Inc.
INDUSTRY